One-Month DAPT in CABG Patients

Description

The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.

Conditions

Chronic Coronary Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.

One Month Dual Antiplatelet Therapy With Ticagrelor in Coronary Artery Bypass Graft Patients

One-Month DAPT in CABG Patients

Condition
Chronic Coronary Disease
Intervention / Treatment

-

Contacts and Locations

New York

Weill Cornell Medicine, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥18 years
  • * Elective first-time CABG with use of ≥1 saphenous vein graft;
  • * Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years.
  • * Any indication for dual antiplatelet therapy, including
  • * Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI)
  • * Recent PCI requiring continuation of dual antiplatelet therapy after CABG
  • * Current or anticipated use of oral anticoagulation;
  • * Paroxysmal, persistent or permanent atrial fibrillation;
  • * Any concomitant cardiac or non-cardiac procedure;
  • * Planned cardiac or non-cardiac surgery within one year;
  • * Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy \<5 years;
  • * Inability to use the saphenous vein;
  • * Contraindications to the use of aspirin;
  • * Contraindications to the use of ticagrelor, including
  • * Known hypersensitivity to ticagrelor
  • * Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding)
  • * History of intracranial hemorrhage
  • * Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir)
  • * Inability to undergo coronary computed tomographic angiography (CCTA);
  • * Participating in another investigational device or drug study;
  • * Women of childbearing potential
  • * Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Weill Medical College of Cornell University,

Marc Ruel, MD, MPH, PRINCIPAL_INVESTIGATOR, Ottawa Heart Institute Research Corporation

Mario Gaudino, MD, PhD, MSCE, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

2031-01